Clinical study of lenvatinib in the treatment of hepatitis virus-related hepatocellular carcinoma and antiviral therapy

• Main Authors: Xiaomi Li (Author), Jingyan Wang (Author), Xiaoyan Ding (Author), Yawen Xu (Author), Minghua Yu (Author), Hongxiao Wu (Author), Na Deng (Author), Wei Li (Author), Jinglong Chen (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Lenvatinib is recommended as a first-line tyrosine kinase inhibitor for advanced hepatocellular carcinoma (HCC) since 2017. The aim of this study was to compare the clinical action of lenvatinib in hepatitis B virus (HBV)-related HCC and hepatitis C virus (HCV)-related HCC.Methods: A con...